MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) announced that its Phase 2a clinical protocol for Ketamir-2, an oral NMDA receptor modulator, has ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE